AstraZeneca reports Phase II ZD6474 data

AstraZeneca (LSE:AZN; AZN) said preliminary data from two Phase II trials of its Zactima ( ZD6474) support the company's decision to begin Phase III trials later this year. In Trial 003, an international Phase II study in 168 evaluable patients with advanced non-small cell lung cancer (NSCLC), Zactima met the primary endpoint of improved time to progression (TTP) compared with AZN's Iressa gefitinib (p=0.011). In Trial 006, a Phase II study in advanced NSCLC patients, the combination of 100 mg Zactima plus docetaxel gave a median TTP of 18.7 weeks versus 12 weeks for docetaxel alone -- a difference that was not statistically significant. ...